BioSpace News Archive

Equillium, Inc. today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities.

The Centers for Medicare & Medicaid Services revised the National Coverage Determination of allogeneic hematopoietic stem cell transplantation for individuals with myelodysplastic syndromes due to a request for reconsideration prepared by The American Society of Hematology, the American Society for Transplantation and Cellular Therapy®, the National Marrow Donor Program, and the Center for International Blood and Marrow Transplant Research on January 5, 2024.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.